ArticleERJ open research2025
Larger quality-of-life gains with an asthma support app: a randomised controlled trial.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05248126 (Standard Patient Training Versus Vik Chatbot Guided Training), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Standard Patient Training Versus Vik Chatbot Guided Training: a Randomized Controlled Trial for Asthma Patients
Who cites it
1 citing paper in PubMed.
- Harnessing Machine Learning and Electronic Health Record Data to Improve Asthma Management.Current allergy and asthma reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Smartphone applications present an opportunity to offer timely and personalised care to asthma patients. The aim of the study was to determine whether a Chatbot-based application for asthma patients providing educational content and direct access to pulmonology staff improves quality of life, compared with standard therapeutic education. Methods: This prospective randomised controlled trial (1:1) occurred from 24 May 2022 to 27 October 2023. Patients in the Chatbot group had access to a Chatbot-based, educational smartphone application incorporating Global Initiative for Asthma (GINA) recommendations, and an algorithm validated by experts, including a member of the GINA scientific committee. By interacting with the Chatbot, patients could trigger a mechanism that directly alerted the pulmonology team when patient follow-up was required. The controls (Standard group) partook in standard therapeutic asthma education training. The primary outcome was change in Asthma Quality of Life Questionnaire (AQLQ) scores from baseline to 6 months. Results: 48 of 69 (69.57%) of patients (mean±sd age, 48.43±16.38 years) were female. 29 of 34 (85.3%) in the Chatbot and 29 of 35 (82.9%) in the Standard group had severe asthma (GINA 4-5). Baseline AQLQ, asthma control (ACQ5) and spirometry metrics did not differ between groups. After adjustment, multiple regression analysis indicated that improvements in AQLQ scores were greater in the Chatbot group than in the Standard group (standardised β=0.279, 95% CI 0.004-0.555; p=0.047). Changes in ACQ5 and spirometry metrics did not differ between groups. Conclusions: Use of the Chatbot-guided application for asthma education and support was associated with greater improvements in quality of life than standard therapeutic education.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.